accountHuntington���s disease in a Phase 3 trial. The company, which has been collaborating on the drug with Pfizer Inc., said it would discontinue development of the treatment for Huntington���s and continue its study of dimebon in patients who are taking...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Stocks to Watch: NYSE Euronext, Level 3, Global Crossing
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account